Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG5 siRNA is a small interfering RNA designed to silence the expression of the Autophagy-related 5 (ATG5) gene. ATG5 is an essential protein for the formation of autophagosomes, playing a central role in the autophagy pathway. By knocking down ATG5, researchers can inhibit autophagy to investigate its role in cell survival, apoptosis, and disease progression. In experimental settings, ATG5 siRNA has been used to study its effects on various conditions, including multiple myeloma, lung cancer, hepatocellular carcinoma, and inflammatory diseases like asthma and colitis. It is frequently employed to determine whether a drug's effect is mediated through autophagy or to sensitize cancer cells to chemotherapy by blocking protective autophagy. While primarily used as a research tool, it represents a potential therapeutic strategy for diseases where autophagy contributes to pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atg5 siRNA.